Human Genome (NASDAQ: HGSI) closed at $19.97. HGSI's Benlysta, a lupus treatment, is expected to have phase 3 data released on November 2. HGSI November option implied volatility is at 249, December is at 170, January is at 143 and April is at 112, according to Track Data, suggesting large movement.

NASDAQ 100 (NASDAQ: QQQQ) overall implied volatility at 24; 26-week average is 28.

Semiconductor Holders Trust-SMH overall volatility at 29; 26-week average is 33.

Options Update: Human Genome November volatility at 248 into data originally appeared on BloggingStocks on Fri, 30 Oct 2009 08:00:00 EST. Please see our terms for use of feeds.

Human Genome (NASDAQ: HGSI) is recently trading at $11.07 in pre-open trading, above its close of $3.32. Human Genome Sciences and GlaxoSmithKline (NYSE: GSK) announced that BENLYSTA met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus. HGSI August 2.5 straddle is priced at $2.45, October 2.5 straddle is priced at $2.75, January 2.5 straddle is priced at $3.25 according to Track Data, suggesting large price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Options Update: Human Genome options expensive; shares up 215% originally appeared on BloggingStocks on Mon, 20 Jul 2009 08:00:00 EST. Please see our terms for use of feeds.

• Deutsche Bank downgraded shares of Procter & Gamble (NYSE:PG) to Hold from Buy on valuation and their expectation for slowing short-term industry growth, especially in beauty.
  
• Citigroup downgraded Human Genome (NASDAQ:HGSI) to Hold from Buy as they believe giving up Syncria's royalties removes an important value driver for the stock.
  
• HSBC downgraded shares of Arcelor Mittal (NYSE:MT) to Neutral from Overweight on valuation and believes the company needs to raise prices more than costs have risen for iron ore, coking coal and steel scrap.

• BAE Systems (NASDAQ:BAESY) was cut to Equal Weight from Overweight at Morgan Stanley.
  
• Merrill downgraded Zoltek (NASDAQ:ZOLT) to Neutral from Buy.
  
• Credit Suisse downgraded Illinois Tool Works (NYSE:ITW) and International Paper (NYSE:IP) to Neutral from Outperform.

Analyst downgrades: PG, HGSI and MT originally appeared on BloggingStocks on Thu, 17 Apr 2008 11:07:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Caris initiated shares of Athenahealth (NASDAQ: ATHN) with an Average rating and $26 target, as they believe an unachievable growth rate is priced into shares at current levels.
• Brocade Communications Systems (NASDAQ: BRCD) was initiated with a Neutral rating at UBS.
  
• Royal Bank of Scotland (NYSE: RBS) was initiated with an Underweight rating at Lehmen.
  
• JP Morgan resumed coverage of Human Genome Sciences (NASDAQ: HGSI) with a Neutral rating.

• Lazard resumed coverage of Zoran (NASDAQ: ZRAN) with a Hold rating and Sigma Designs (NASDAQ: SIGM) with a Buy rating.
  
• Stifel initiated Tortoise Energy Capital (NYSE: TYY) with a Buy rating and $32 target.
  
• HSBC initiated DSG International (OTC: DSITY) with an Overweight rating.

Analyst initiations: ATHN, BRCD, RBS and HGSI originally appeared on BloggingStocks on Thu, 01 Nov 2007 11:20:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Morgan Keegan started Logitech International SA (NASDAQ: LOGI) with an Outperform rating; the firm believes Logi is well positioned in the peripherals market and should continue to see solid growth driven by increasing PC use as multimedia devices.

• Time Warner Cable Inc (NYSE: TWC) was initiated with an Overweight rating and $52 target at Prudential, as the firm sees upside to guidance and views valuation as reasonable.

• Human Genome Sciences (NASDAQ: HGSI) was initiated with a Hold rating at Stanford, citing lack of visibility into Albuferon, LymphoStat-B and HGS-ETR programs for its rating...

• Morgan Stanley initiated Hanesbrands Inc (NYSE: HBI) with an Overweight rating.

• Bernstein started M&T Bank Corp (NYSE: MTB) with a Market Perform rating and $121 target.

• MV Oil Trust (NYSE: MVO) was initiated at AG Edwards with a Buy rating, as the firm believes MV Oil offers investors tax-advantaged exposure to oil price volatility and development activity.

• Lehman Brothers started Downey Financial Corp (NYSE: DSL) with an Outperform rating and $80 target.

Analyst initiations 3-01-07: Logitech started with an Outperform rating at Morgan Keegan originally appeared on BloggingStocks on Thu, 01 Mar 2007 11:45:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Citing risks to Albuferon and Lympho-Stat, Morgan Stanley initiated Human Genome Inc (NASDAQ: HGSI) with an Underweight rating and $8 target.

• Bear Stearns started shares of Trump Entertainment Resorts Inc (NASDAQ: TRMP) with a Peer Perform rating as they believe Street estimates are too high, the company lacks development opportunities outside of Atlantic City, and uncertainty stemming from the new Atlantic City smoking ban.

• Lehman Bros started Isis Pharmaceuticals Inc (NASDAQ: ISIS) with an Overweight rating and $20 target.

• Leerink Swann initiated HealthSouth Corp (NYSE: HLS) with an Outperform rating and was added to the Focus List; one of the firm's consultants performed an analysis of the company's in-patient rehab business in order to determine the impact of the 75% rule after it is completely implemented, as well as determining the opportunities from market consolidation. As a result of the analysis, the firm believes that the company is in a good position to successfully navigate the phase-in of the 75% rule.

• Pali Capital initiated China Mobile Ltd (NYSE: CHL) with a Buy rating and $66 target, based on expectations of sustaining total subs growth over 20%.

Analyst initiations 1-29-07: Human Genome carries some risk originally appeared on BloggingStocks on Mon, 29 Jan 2007 11:13:00 EST. Please see our terms for use of feeds.